Hyperion Therapeutics (FRA:0HY) Net-Net Working Capital : €3.88 (As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Hyperion Therapeutics's Net-Net Working Capital for the quarter that ended in Mar. 2015 was €3.88.

The industry rank for Hyperion Therapeutics's Net-Net Working Capital or its related term are showing as below:

FRA:0HY's Price-to-Net-Net-Working-Capital is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.9
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Hyperion Therapeutics Net-Net Working Capital Historical Data

The historical data trend for Hyperion Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics Net-Net Working Capital Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Net-Net Working Capital

-134.87

3.47

2.98

4.04

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Net-Net Working Capital	Get a 7-Day Free Trial													3.44	-0.42	3.58	3.99	3.88

Competitive Comparison of Hyperion Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, Hyperion Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyperion Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyperion Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Hyperion Therapeutics's Price-to-Net-Net-Working-Capital falls into.

Hyperion Therapeutics Net-Net Working Capital Calculation

Hyperion Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2014 is calculated as

	Net-Net Working Capital		(A: Dec. 2014 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(111.337	+	0.75 * 12.055	+	0.5 * 3.748	-	39.628
-	0	-	0)	/	20.470
=	4.04

Hyperion Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2015 is calculated as

	Net-Net Working Capital		(Q: Mar. 2015 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(118.86	+	0.75 * 19.91	+	0.5 * 5.172	-	50.682
-	0	-	0)	/	22.079
=	3.88

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Hyperion Therapeutics (FRA:0HY) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Hyperion Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics (FRA:0HY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics (FRA:0HY) Headlines

No Headlines